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Graphical abstract 
 
Abstract  
 
We evaluated whether the lack of TNF-α signaling increases mucosal levels of Annexin A1 
(AnxA1); the hypothesis stems from previous findings showing that TNF- neutralization in 
Crohn´s disease patients up-regulates systemic AnxA1 expression. Biopsies from healthy 
volunteers and patients under anti-TNF-α therapy with remittent ulcerative colitis (UC) showed 
higher AnxA1 expression than those with active disease. We also evaluated dextran sulfate 
sodium (DSS)-acute colitis in TNF- receptor 1 KO (TNFR1-/-) strain with impaired TNF- 
signaling and C57BL/6 (WT) mice. Although both strains developed colitis, TNFR1-/- mice 
showed early clinical recovery, lower myeloperoxidase (MPO) activity and milder 
histopathological alterations. Colonic epithelium from control and DSS-treated TNFR1-/- mice 
showed intense AnxA1 expression and AnxA1+ CD4+ and CD8+ T cells were more frequent in 
TNFR1-/- animals, suggesting an extra supply of AnxA1. The pan antagonist of AnxA1 
receptors exacerbated the colitis outcome in TNFR1-/- mice, supporting the pivotal role of 
AnxA1 in the early recovery. Our findings demonstrate that the TNF- signaling reduction 
favors the expression and biological activity of AnxA1 in inflamed intestinal mucosa. 
 
 
Key words: therapy; DSS-induced colitis; inflammation; gut; epithelium. 
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1. Introduction 
 
Annexin A1 (AnxA1) is a phospholipid binding protein able to inhibit leukocyte transmigration 
and activation. Originally described as a glucocorticoid (GC)-induced factor with anti-
phospholipase activity, later on AnxA1 has been implicated in prevention of inflammation in 
several disease models, such as peritonitis, air-pouch edema, myocardium infarct, respiratory 
tract allergy, endotoxemia, kidney ischemia/reperfusion, uveitis, arthritis and others [1-9]. 
AnxA1 binds to formyl peptide receptors (FPR) [10] and supports the resolution of inflammation 
and the wound healing suggesting a protective role on the intestinal epithelium damage [11-14].  
 
Inflammatory bowel diseases (IBD) are chronic gut illnesses. Between them, ulcerative colitis 
(UC) is a prevailing entity with continuous superficial colonic inflammation, abdominal pain and 
recurrent diarrhea [15]. The proposed mechanism for UC development is the breakdown of the 
interaction between environmental stimuli and gut microbiota that results in mucosal 
inflammation [16]. This change may include disruption of the barrier function and alteration in 
the regulation of acute and adaptive immune responses [17].  
 
The pro-inflammatory cytokine TNF-α plays a pivotal role in the signaling cascade that causes 
chronic intestinal inflammation in IBD [18]. Biologic agents such as anti-TNF-α antibodies 
Infliximab (IFX) and Adalimumab (ADA) attenuate the inflammatory process and have been 
approved for the treatment of moderate-to-severe UC that is refractory to conventional therapy 
[19]. These antibodies are well tolerated, induce and maintain clinical remission and mucosal 
healing, and permit the tapering of corticosteroids while allow remission [19, 20]. Interestingly, 
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the anti-TNF-α therapy produces early changes in the gene expression profiles of intestinal 
epithelial cells that could be predictive of clinical responses [21, 22]. The availability of 
predictive correlates of clinical response is highly relevant as could enable to determine the 
benefits or risks of enduring biologic therapies on individual basis. In agreement, in a 
longitudinal assessment of peripheral blood samples from IBD patients recently we showed that 
systemic mononuclear cell transcripts as well as plasma levels of the anti-inflammatory 
biomarker AnxA1 are affected by initial and continuous IFX therapy [23]. Surprisingly, the 
response correlated with lower C-reactive protein and better quality of life of these patients.  
 
We hypothesized that the absence or reduction of TNF-α signaling could amplify mucosal levels 
of the protein AnxA1. Herein, biopsies from patients under anti-TNF-α therapy during UC 
remission showed an increase in mucosal AnxA1 expression. We also used mice lacking TNFR1 
(transmembrane and soluble receptor of TNF-α) to mimic the activity of anti TNF-α antibody, 
and we examined the expression and anti-inflammatory activity of AnxA1 in the colon mucosa 
in the well characterized animal model of dextran sulfate sodium (DSS) induced colitis. We 
found that the blockade of the TNF-α pathway upregulated the AnxA1 expression in the 
epithelium and colon mucosa and simultaneously accelerated the resolution process of the colitis. 
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2. Methods 
 
2.1 Ethic statement  
This study was approved by the Ethics Committee of the Hospital Privado-Centro Medico de 
Córdoba (Approval Number HP 4-215). All patients medically assisted in the 2013 year gave 
their written informed consent prior to participation in this study. Animal experiments were 
approved by and conducted in accordance with guidelines of the Committee for Animal Care and 
Use of the Chemical Science Faculty, National University of Cordoba. (Approval Number HCD 
15-09-69596) in strict accordance with the recommendation of the Guide to the Care and Use of 
Experimental Animals published by the Canadian Council on Animal Care (OLAW Assurance 
number A5802-01). Our animal facility obtained NIH animal welfare assurance (assurance no. 
A5802-01, Office of Laboratory Animal Welfare, NIH, Bethesda, MD, USA). 
 
2.2 Patients 
Colonic mucosal biopsies were obtained from healthy individuals without history of UC (healthy 
volunteers, n=3) undergoing colonoscopy for colorectal cancer screening and individuals with 
UC. Patients with UC (n=11) fell between four groups: with active disease without previous 
therapy (no therapy, n=6); with clinical response on maintenance therapy with either GC (n=2) 
or anti-TNF-α therapy (anti-TNF-α group, n=3). Patient characteristics such as gender, age and 
clinical data obtained from medical records are displayed in Table 1. Mucosal biopsies were 
taken from the left colon in close proximity to biopsies used for histological assessment and 
fixed in 10% neutral-buffered formalin.  
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2.3 Immunohistochemistry 
For AnxA1 expression analysis, 5 m sections were incubated in 3% H2O2 for 25 min and then 
incubated for 30 min in 10 mM citrate buffer (pH 6.0), followed by 20 min in distilled water. 
Sections were blocked in 10% normal serum, and incubated with rabbit anti-human-AnxA1 
(clone MRQ3, Cell Marque, California, USA) for 45 min at room temperature. Sections were 
washed in phosphate buffer saline (PBS), incubated with anti-rabbit biotinylated secondary 
antibody (Dako North America Inc. California, USA) and visualized by avidin-biotin-peroxidase 
detection. For the enzymatic reaction diaminobenzidine (DAB) (Vector Laboratories, California, 
USA) was used as the chromagen for 8 min, and sections counterstained with Mayer’s 
hematoxylin (Sigma Aldrich, San Luis, MO, USA) for 5s. Images were taken with a Nikon 
optical microscope (Nikon Eclipse TE2000-U, Melville, USA). Densitometric analysis for 
AnxA1 staining was performed using the ImageJ software and displayed as an arbitrary scale 
ranging from 0 to 255 units. 
 
2.4 Mice 
Male and female 6-8-wk-old mice C57BL/6 (WT, the Jackson Laboratory, California, USA ) and 
6-8-wk-old TNF- receptor 1 KO (TNFR1-/-, kindly provided by Dr. Silvia DiGenaro, National 
University of San Luis, Argentina) were used in these studies. For each group of experiments, 
mice were matched by age, sex, and body weight. Animals were maintained in specific 
pathogen-free conditions, housed in collective cages at 22 ± 1°C under a 12-hour light/dark cycle 
(lights on at 7:00 a.m.), with free access to laboratory chow and drinking water. Experiments 
were performed during the light phase of the cycle.  
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2.5 Induction and assessment of DSS-induced colitis 
Mice received a solution of filtered water containing 3% (w/v) DSS (MW 40 000 kDa, Dextran 
Prod Ltd, Ontario, Canada) ad libitum over a 5-day period. Every other day, the DSS solution 
was replenished and at the end of this period, DSS was replaced by normal drinking water for 2 
days.  Control mice received only normal drinking water. All animals were examined once a day 
and the disease activity index (DAI) was assessed during 18 days as described previously [24, 
25] [25, 26]. Briefly, DAI was the combined score of weight loss, stool consistency, and 
bleeding.  For weight loss, a value of 0 was assigned if body weight increased or remained 
within 1% of baseline, 1 for a 1% to 5% loss, 2 for a 5% to 10% loss, 3 for a 10% to 15% loss, 
and 4 for weight loss >15%. For stool consistency a value of 0 was for no diarrhea, 2 for loose 
stool that did not stick to the anus and 4 for liquid stool that did stick to the anus. For fecal blood, 
0 was for none, 2 for moderate, and 4 for gross bleeding. Mice were humanely sacrificed on days 
5, 7, 10 and 18 by cervical dislocation. Colons were removed and examined for weight, 
macroscopic appearance and length (which were measured from 1 cm above the anus to the top 
of the cecum).  
 
2.6 Myeloperoxidase assay 
Neutrophil infiltration was assessed indirectly by measuring myeloperoxidase (MPO) activity in 
colon samples. The MPO assay was performed as described previously (26). On day 7, animals 
were killed and colon tissue segments were homogenized in 5% EDTA/NaCl buffer (pH 4.7) and 
centrifuged at 10 000 × g for 15 min at 4°C. Pellets were resuspended in 0.5% hexadecyl 
trimethyl ammonium bromide buffer (pH 5.4), and samples were frozen in liquid nitrogen and 
thawed three times. On final thawing, the samples were similarly centrifuged, and 25 μl of the 
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supernatant was used for MPO assay. The MPO enzymatic reaction was assessed by the addition 
of 1.6 mmol/L tetramethylbenzidine, 80 mmol/L NaPO4 and 0.3 mmol/L H2O2. The absorbance 
was measured spectrophotometrically at 690 nm and MPO was calculated with a standard curve 
generated for each experiment. Results were expressed in optical density as ng/mg tissue protein. 
 
2.7 Histopathological analysis 
Excised portions of the distal colon were fixed immediately in a 4% (w/v) formaldehyde solution 
and embedded in paraffin. Next, 5 μm sections were mounted on glass slides, and deparaffinized. 
For histological analysis, slices were stained using standard H&E techniques. For kinetic 
evaluation, we defined the histological score that represents the scoring sum of histoarchitecture 
alterations, mononuclear and polymorphonuclear infiltrate in epithelium, lamina propria (LP) 
and submucosa, crypt alterations, pseudopolip formation, edema and ulcers, as described [26].  
Images were taken with a Nikon optical microscope (Nikon Eclipse TE2000-U, USA). 
 
2.8 Immunofluorescence 
Sections of the distal colon were embedded in Optimal Cutting Temperature Compound (Tissue-
Teck O.C.T. compound, Sakura Finetek Europe B.V., The Netherlands).  Sections (5 μm) were 
blocked with 3% w/v bovine serum albumin (BSA, Sigma Aldrich, San Luis, MO, USA) for 1 h 
and incubated with 1:400 rabbit anti-mouse AnxA1 antibody overnight at 4°C, washed, and 
incubated for 1 h with 1:100 fluorescein isothiocyanate  (FITC) labeled goat anti rabbit 
secondary antibody (Sigma Aldrich, San Luis, MO, USA). All incubations were carried out in a 
humidity chamber.  Nuclei were counterstained with DAPI and slides were mounted in Aqueous 
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Mounting Medium with fluorescence tracers (FluorSave, Calbiochem, USA). Images were taken 
with a Confocal Olympus Fluoview 1000 microscope (Olympus, USA).  
2.9 Explant cultures  
Colons were flushed with RPMI and opened along the longitudinal axis. Then, 10 mm2 punch 
biopsies were obtained from the medial colon and incubated for 24 h in RPMI supplemented 
with 10 % fetal bovine serum (FBS) and antibiotics (one punch biopsy per 1 ml medium). 
Supernatants were collected and kept in -20 ºC to assess IL-6 production by ELISA (BD 
Biosciences, California, USA), as specified by the manufacturers or AnxA1 by Western blot  
with the rabbit anti-mouse AnxA1 antibody, as described [27]. The amount of 10 l of total 
protein in each colon explant supernatant sample was employed for analysis [28, 29].  
 
2.10 Isolation of lamina propria cells and flow cytometry analysis 
Isolation of colonic LP cells was performed as previously with slight modifications [30]. Briefly, 
extraintestinal fat tissue and blood vessels were carefully removed and colons were flushed with 
cold PBS, opened longitudinally and cut into small pieces. Epithelial cells and mucus were 
removed by 45 min incubation in RPMI containing 5% FCS and 2 mM EDTA and 1 mM 
dithiothreitol (DTT) (Sigma Aldrich, San Luis, MO, USA) at 37ºC with 250 rpm shaking. Colon 
pieces were then digested in PBS containing 5% FBS, 1 mg/ml Collagenase IV (Sigma Aldrich, 
San Luis, MO, USA) for 90 min and 37ºC shaking at 250 rpm. The digested cell suspension was 
washed with PBS and passed through 40 µm cell strainers. Isolated 1×106 LP cell aliquots were 
resupended in FACS buffer (PBS, 5% FBS, 0.02% NaN2) containing FBS 10% on ice for 15 
min to prevent non-specific antibody binding. Thereafter samples were resuspended in FACS 
buffer containing CD3 (PECy7), CD4 (PE), CD8 (PERCP) and CD11b (APC) antibodies at the 
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concentration suggested by the manufacturers. For intracellular staining, samples were 
resuspended in FACS buffer containing 1% paraformaldehyde for 15 min and thereafter in 
CytoFix/CytoPerm buffer (BD Biosciences, California, USA) for 1 h and washed in the 
PermWash buffer (BD Biosciences, California, USA). The anti-AnxA1 antibody was added at 
1:100 dilution from stock solution of 1.0 mg/ml. The FITC-conjugated anti-mouse IgG (Sigma 
Aldrich, San Luis, MO, USA) was used at 1:400 dilution and incubated on ice for 30 min. On the 
basis of forward and side light scatter, debris and dead cells were gated out; 100 000 events were 
analyzed using a FACSAria flow cytometer (BD Bioscience, California, USA). Determination of 
positive and negative populations was performed based on the control staining with an irrelevant 
IgG isotype labeled with FITC, PE, PerCP-Cy5.5 or APC. Flow cytometry analysis was done 
with the FlowJo software. 
 
2.11 In vivo BOC2 and anti-AnxA1 treatments 
WT and TNFR1-/- mice received four i.p. injections of BOC2 (N-t-butyloxycarbonyl-Phe-Leu-
Phe-Leu-Phe) (Bachem Americas, California, USA), a pan-antagonist of FPRs [31], once a day 
starting on day 7 after DSS treatment (10 g/Kg, 0.1 ml). BOC2 was dissolved in DMSO, and 
further diluted in PBS on the day of administration. Equivalent concentrations of DMSO were 
used as vehicle controls. In other experiments mice received i.p. 1g of rabbit anti-murine 
AnxA1 antibody (Invitrogen, Grand Island, USA) in 100 l PBS during 3 days starting on day 1 
of DSS treatment.  
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2.12 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 4 software (GraphPad Software, San 
Diego, CA). Differences between groups were determined by two-way analysis of variance 
followed by a Student-Newman-Keuls test or Mann-Whitney U-test. Data were expressed as 
mean ± SEM; p< 0.05 was considered statistically significant.  
 
3. Results 
3.1 AnxA1 expression in colon from UC patients in remission under anti TNF-α therapy 
Previously, IFX treated Crohn’s patients presented increase of AnxA1 plasma levels and up-
regulation of AnxA1 mRNA transcription in peripheral mononuclear cells [23]. We wondered if 
biological agents such as IFX could also modify levels of AnxA1 in colonic mucosa in IBD 
patients. To address this question we explored the expression and localization of AnxA1 in 
biopsy sections of UC patients either untreated or in remission upon anti-TNF- therapy. For 
comparative purposes we also included UC patients receiving GC as well as healthy volunteers 
(Table 1). The representative section in Fig. 1A shows lower expression of AnxA1 in epithelial 
cells from an untreated active UC patient (asterisks); in contrast, higher AnxA1 immunostaining 
was observed in crypts and surface epithelium in biopsies from patients with GC- or IFX-
induced remission (arrows) (Fig. 1B, C), although without reaching the AnxA1 immunostaining 
observed in biopsies from healthy volunteers (Fig. 1D). The intensity of epithelial AnxA1 
expression is displayed in the Figure 1E in densitometric units. Our previous findings [24] 
together with the higher levels of AnxA1 found in patients under anti-TNF- therapy prompted 
us to evaluate the interplay between TNF- and AnxA1 levels. 
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3.2 TNFR1-/- mice exhibit early resolution of acute colitis 
To evaluate the putative TNF-/AnxA1 axis in colitis we used the DSS acute model in C57BL/6 
and TNFR1-/- mice. Signs were evaluated until day 18, as we previously found that the acute 
colitis reaches a complete clinical resolution in the knockout group (data not shown). Oral 
administration of DSS for 5 days provoked colitis in both strains; in the acute period, around 
days 5-7, WT and TNFR1-/- animals showed similar clinical signs with increased DAI and 
weight loss compared with control groups (Fig. 2A, B).  By day 8, TNFR1-/- mice exhibited a 
significant reduction of DAI as well as weight recovery compared with WT animals (Fig. 2A, B). 
Macroscopically, the colon length shortening found in WT animals on days 10 and 18 (p<0.05) 
was not present in DSS-treated TNFR1-/- mice (Fig. 2C).  
 
We wondered whether the resolving profile of mice with attenuated TNF- signaling could be 
associated with differences in the inflammatory response in the intestinal mucosa. Microscopic 
observation of colon sections showed no histopathological changes in control groups of both 
strains (Fig. 3A, B). In contrast, DSS-treated WT and TNFR1-/- mice exhibited marked cellular 
infiltration into colonic mucosa by day 5 (Fig. 3C, D). The localization of polymorphonuclear 
cells (PMN) in TNFR1-/- mice was mainly intravascular while in WT animals, cells infiltrated 
massively the LP (Fig. 3C and D, insets). Yet, the histopathological score in knockout group was 
significantly lower (p< 0.05) as other tissue alterations taken into account in this parameter such 
as ulcers, crypt alterations and edema were smaller (Fig. 3I). On days 10 and 18, the 
histopathological analysis revealed transmural inflammation with lymphoid follicles, polypoid 
processes and atypical dysplastic crypts with abscesses, particularly in WT mice (Fig. 3E, G). 
TNFR1-/- mice instead showed more preserved histoarchitecture with signs of regeneration (Fig. 
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3F, H) and re-epithelialization by squamous epithelium (Fig. 3H, inset). The scoring sum of 
histopathological alterations displayed significant differences between both mouse strains (Fig. 
3I).  
 
Additionally, PMN infiltration into the colon mucosa was measured indirectly by MPO activity. 
As shown in Fig. 3J, DSS-treated WT and TNFR1-/- mice presented mild increase in colonic 
levels of MPO on day 5, compared with control animals. Subsequently, on days 10 and 18, MPO 
was barely detectable in knockout mice whereas WT group showed significantly higher levels of 
the enzyme. Moreover, in colon explant culture supernatants, TNFR1-/- mice exhibited lower 
levels of the pro-inflammatory cytokine IL-6 both in acute (day 5) and in resolution (days 10-18) 
steps of DSS-induced colitis compared with WT animals (data not shown).  
 
3.3 AnxA1 expression increases in the intestinal mucosa of TNFR1-/- during colitis 
resolution 
To address if early recovery of colitis in TNFR1-/- mice could be related to different amount of 
AnxA1 in intestinal mucosa we evaluated AnxA1 immunoreactivity in colon sections of TNFR1-
/- and WT mice. Even before the inflammatory challenge, control TNFR1-/- mice exhibited more 
intense expression of AnxA1 than control WT animals (Fig. 4A and D). Furthermore, during the 
recovery period (days 10-18), mice with reduced TNF- signaling showed higher expression of 
AnxA1 (Fig. 4E and F), with specific localization in the crypt epithelium (arrows) (Fig. 4F).  
None reactivity was detected in immunohistochemistry controls lacking the anti-AnxA1 antibody 
(Fig. 4G). 
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Also, AnxA1 was detected in supernatants of colon explant cultures before and at the end of the 
recovery period (Fig. 4H), as previously found by others in bronchoalveolar lavage fluid [28]. 
Consistent with the immunofluorescence results, control and DSS-treated TNFR1-/- mice 
exhibited significantly higher AnxA1 levels released by colonic mucosa (Fig. 4I).  
 
 
We also assessed if immune cells could be contributing to the AnxA1 supply in the tissue. For 
this purpose, we isolated LP cells from WT and TNFR1-/- colons and we evaluated 
surface/intracellular AnxA1 expression by flow cytometry. Again, before the inflammatory 
challenge, the frequency of AnxA1+ CD11b+ cells was higher in control knockout animals (Fig. 
4I), although on day 18, the contribution of this subset was similar in both strains. Interestingly, 
the frequency AnxA1+ CD4+ and CD8+ T cells augmented significantly by day 18 in TNFR1-/- 
mice (p< 0.05), which is consistent with a recent study demonstrating the ability of AnxA1+ T 
cells to attenuate T cell-driven inflammatory responses [32]. 
 
3.4 Attenuation of the early recovery of colitis in TNFR1-/- mice upon blockade of AnxA1 
receptors  
To confirm that the milder colitis in absence of TNF- signaling was due to AnxA1 
expression/activity we treated the TNFR1-/- C57BL/6 strains with BOC2, the pan-antagonist of 
FPR [32]. This receptor mediates the biological effects of AnxA1 and AnxA1 derived peptide 
Ac2-26 [5]. On day 7 after DSS treatment we injected i.p. BOC2 during 4 days and we evaluated 
colitis outcome and resolution until day 11, both in WT and TNFR-/- C57BL/6  strains. BOC2 
had no effect when given alone to control WT and TNFR-/- mice (Fig. 5). The colitis outcome in 
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WT mice remained unmodified upon BOC2 treatment, in agreement with a less prevailing 
activity of AnxA1 when the TNF- signaling was intact (Fig. 5A and B). Remarkably in the 
DSS+BOC2 TNFR1-/- group the antagonist was able to prevent the early DAI attenuation and 
the observed weight recovery (Fig. 5C and D). Moreover, colon sections of DSS+BOC2 TNFR1-
/- group showed strong tissue damage and profuse inflammation, as can be seen in representative 
microphotographs  (Fig. 6A) associated to higher MPO levels (Fig. 6B), demonstrating that FPR 
blockade overrides the anti-inflammatory/pro-resolving function of increased AnxA1. In 
additional experiments, TNFR1-/- mice were injected i.p with anti-AnxA1 antibody during 3 
days after starting DSS dispense. Although the neutralizing anti-AnxA1 dose administered was 
not enough to change the clinical signs in the evaluated mice, the treatment provoked the 
increase of IL-6 production by colon explants (data not shown).  
 
4. Discussion  
 
Many reports support the intimate relationship of TNFR1 expression and signaling with the 
pathogenesis of inflammatory diseases. Some studies have explored the presence of protein 
biomarkers in serum/plasma of patients with rheumatoid arthritis treated with IFX, one of the 
major anti-TNF-α drugs [33, 34]. Mainly, up- or down- differentially regulated proteins were 
apolipoproteins, components of the complement system and acute phase reactants [33, 34].  
 
Herein we found that patients who were experiencing an UC flare, with diarrhea, bloody feces, 
abdominal pain and others clinical and biochemical signs did not express AnxA1 in epithelium. 
In contrast, UC patients in remission treated with anti-TNF (low number of clinical signs, 
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colonoscopy and histopathology with moderate grade) presented increased AnxA1 protein in 
intestinal mucosa, particularly in the crypts and surface epithelium. This result was similar to 
those two patients receiving GC, which presented more clinical signs, probably because the 
AnxA1 is a GC-inducible protein. Even though the number of patients was limited, the data were 
in agreement with our recent work which revealed the increased expression of systemic AnxA1 
in mononuclear cells from patients with Crohn’s Disease after IFX treatment [23] and prompted 
us to evaluate the interplay between TNF- and AnxA1 levels in colitis. 
 
To validate clinical observations, we used the well known model of DSS-induced colitis in 
TNFR1-/- and WT C57BL/6 mice. In our hands, both strains developed a similar colitis until 
days 7-8. However, clinical signs, histopathology and inflammatory biomarkers, such as MPO, 
returned to baseline levels in knockout earlier than in WT mice, suggesting a detrimental role for 
TNFR1 in the resolution of acute inflammation. In agreement, other studies demonstrated that 
TNFR1 ablation attenuated tissue damage after trinitrobenzene sulphonic acid (TNBS) induced 
colitis [35], which was related to control of NF-κB activity [36]. Yet, previous reports 
demonstrated that TNFR1 or TNFR2 deficiency led to exacerbation of colitis signs compared 
with WT counterparts [36, 37] and that TNFR1-/- strain had more weight loss and increased 
mortality after TNBS instillation or DSS intake, respectively [37-39]. Mice lacking NEMO in 
intestinal epithelial cells (NEMOIEC-KO mice) at young age develop severe pancolitis affecting all 
parts of the colon distal from the caecum; double NEMO IEC-KO/TNFRI-deficient mice did not 
show macroscopic or histological signs of colitis demonstrating that TNFRI signalling is crucial 
for disease pathogenesis in this model [40]. Overall, these studies highlight the complexity of the 
TNF signaling via TNFR1 or TNFR2 in colitis during the onset and perpetuation of intestinal 
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inflammation, which may be affected by different TNFR expression patterns and distinct colitis 
models used. In fact, the background  of the strains, the mechanism of inflammation induction, 
the acute or chronic colitis model, the innate vs. Th1 immune response shape different 
experimental conditions that  are useful to study the TNF-TNFR axis but do not necessarily 
reproduce the disease mechanism. 
 
The blockade of TNF-TNFR signaling seems to induce the amelioration of inflammatory 
diseases through apoptosis induction, cytokine suppression and activation of regulatory cells [35-
37]. Consistently, we found higher AnxA1 expression in the colonic epithelium of TNFR1-/- 
mice before the inflammatory challenge and along the resolution of DSS-colitis, in agreement 
with previous reports [41]. On the other hand, epithelial AnxA1 expression was abundant in 
crypts and surface epithelium only in TNFR1-/- at later stages, which was concomitant with the 
weight gain, lower DAI and histological recovery in these animals. Together the abrogation of 
TNF-α signaling facilitated AnxA1-mediated activity in gut function in agreement with the 
recent study from Leoni [14] that demonstrates the influence of AnxA1 in the “final act” during 
resolution of inflammation, which requires efficient tissue repair and restoration of mucosal 
homeostasis. As suggested previously, the constant release of AnxA1 by innate immune cells, 
would have a pro-resolving effect on the inflammatory response [42]. Still, as many other 
endogenous anti-inflammatory and pro-resolving mediators, we believe that AnxA1 may be 
functioning to counteract the properties of proinflammatory factors and to ensure a prompt 
resolution of inflammation in the TNFR1-/- colitis model.  
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Furthermore, LP CD11b+ and T cells also seemed to be an important source of AnxA1 in the 
later stage of the study that ended with fully clinical resolution of DSS-colitis in TNFR1-/- mice. 
Interestingly, the effects of AnxA1 evaluated in three distinct models of T cell–mediated 
inflammation indicate that T cell–expressed AnxA1 functions to attenuate T cell–driven 
inflammatory responses via T cell–intrinsic effects on intracellular signaling, proliferation, and 
Th1/Th17 cytokine release [32]. Whether AnxA1 has effects on the regulatory T cells that may 
contribute to the anti-inflammatory actions of this protein on colitis resolution is a possibility that 
remains to be addressed.  
 
In terms of AnxA1 availability, the two mouse strains secreted this protein in colon explant 
supernatants. Yet, at the resolution step, TNFR1-/- mice presented more AnxA1 than WT 
animals. Possibly, the bioactive N-terminal peptide could have been playing the protective role 
in the mucosa in the late stage of colitis. This result suggests that cleaved N-terminal peptide 
could be binding to FPR1 in the TNFR1-/- mouse mucosa promoting the pro-resolving profile.  
 
The in vivo blockade of the AnxA1 signaling by BOC2, a pan-antagonist of the FPR, reverted 
partially the early recovery of colitis in TNFR1-/- mice . The finding suggests that the biological 
actions of AnxA1, enhanced by the lack of TNF- signaling, involve FPR pathways. A study 
using a chronic DSS-colitis model revealed that in FPR1-/- mice, there is no re-
epithelialization of the ulcers, suggesting that this AnxA1 receptor has a protective role in the gut 
inflammation [43]. Also, FPR2 seems to play a more important role in maintaining colonic 
homeostasis and inflammatory responses than FPR1, as shown by decreased epithelial cell 
proliferation and shortened crypts in acute DSS-colitis animals [44]. Furthermore, BOC2 and 
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others FPR antagonists abrogated the effect of AnxA1 and its Ac2-26 peptide in several models, 
such as uveitis [9], mesenteric ischemia/reperfusion [45], sepsis [46], peritonitis [47, 48], 
pleurisy [48] and recently in colitis [14].  
 
Despite its wide tissue distribution and the role of AnxA1 in crucial cellular events, very little is 
known about the regulation of its expression. The novelty of our work is to identify the lack of 
TNF- signaling as a condition that modulates the expression, secretion and function of AnxA1 
on the pro-resolving process of colitis. Altogether, the human and animal studies suggest a role 
of AnxA1 in mediating the anti-inflammatory and protective effects of anti-TNF-α therapy. 
Besides, this molecule could represent a helpful biomarker for monitoring therapeutic efficiency 
in IBD patients. 
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Figure captions 
Figure 1. Human colonic mucosa from healthy volunteers and remittent UC patients under 
anti-TNF-α therapy express more AnxA1. AnxA1 expression was evaluated in sections from 
human biopsies by immunohistochemistry. Representative photomicrographs from UC patients 
without therapy (A), treated with GC (B), anti-TNF-α (C) and healthy volunteers (D). AnxA1 
immunostaining in crypts and surface epithelium (arrows). Densitometry analysis of epithelial 
AnxA1 expression in all samples evaluated (E). Comparisons were performed between groups 
with n ≥ 3. Data are mean ± SEM. Magnification: 200x.  *p<0.05. 
 
 
Figure 2. Earlier clinical resolution of DSS-colitis in TNFR1-/- mice. Mice received 3% DSS 
for 5 days and drinking water for the next 2 days; animals were evaluated daily during 18 days 
for clinical signs to assess (A) the Disease Activity Index (DAI), (B) the weight loss percentage 
and (C) the colon shortening on day 18. (A) and (B): () control WT, () control TNFR1-/-, 
() DSS-treated WT, () DSS-treated TNFR1-/-. Gray box: acute stage. Data are mean ± SEM. 
n = 6-8 animals/group. Experiments were performed twice. (A) and (B) * p< 0.05 vs. DSS-
treated TNFR1-/-; (C) * p< 0.05 vs. control.  
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Figure 3. Tissue injury and inflammation in DSS-treated TNFR1-/- mice. Histopathological 
analysis of representative sections from WT (C, E, G) and TNFR1-/- (D, F, H) mice on days 5, 
10 and 18 after colitis induction. Neutrophil infiltrate localized outside (C) or mainly inside 
blood vessels (D) (white arrows, insets). Progression of DSS-colitis in WT with presence of 
ulcers (asterisk) and tissue infiltrate of PMN (C and inset), dysplasia (asterisk) and crypt 
abscesses (E and inset) and even pseudopolyps (PP) and luminal abscesses at later stages (G and 
inset). WT and TNFR1-/- control groups (A, B); histopathological score on days 5, 10 and 18 
after colitis induction (I); MPO (myeloperoxidase) activity (J). Magnification: 200x. Data are 
mean ± SEM. n = 6-8 animals/group. Experiments were performed twice. # p<0.05 vs. control; 
## p<0.01 vs. control; ### p<0.001 vs. control; *p<0.05 vs. WT; **p<0.01 vs. WT. 
 
 
Figure 4. AnxA1 expression increases in the resolution stage of colitis in TNFR1-/- mice. 
Frozen colon sections from control TNFR1-/- and WT mice (A, D) or after 10 and 18 days of 
colitis induction (B-F) were used for AnxA1 labeling by immunofluorescence. Immunoreactivity 
for AnxA1 in epithelial cells (white arrows) at later stage of colitis (F); Immunohistochemistry 
control (G).  Supernatants of colon explants (1mg of tissue, 10l of total protein) from control or 
DSS-treated WT and TNFR1-/- mice were tested for the presence of AnxA1 by Western blotting 
with a polyclonal rabbit anti-AnxA1 (H); flow cytometry analysis of isolated LP CD11b, CD4 
and CD8 cells stained for AnxA1 (I). Data are mean ± SEM. n = 4 animals/group at each time 
studied. Magnification: 200x. * p<0.05 vs. WT colitis;  # p<0.05 vs. TNFR-/- colitis. 
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Figure 5. Blocking AnxA1 activity exacerbates clinical signs of colitis in TNFR1-/- mice. 
WT and TNFR1-/- mice received 3% DSS for 5 days and drinking water for the next 2 days; 
BOC2 was injected i.p. on days 7-10; animals were evaluated during 11 days for clinical signs 
(A-D) Disease Activity index (DAI) and percentage of weight loss in control (), BOC2 (), 
DSS () and DSS+BOC2 () groups in WT (A,B) and TNFR1-/- (C, D) mice; data are mean ± 
SEM. n = 4 animals/group. *p<0.05 vs. DSS group in TNFR1-/- mice. 
 
 
Figure 6. Blocking AnxA1 activity impairs histopathological signs in TNFR1-/- mice. WT 
and TNFR1-/- mice received 3% DSS for 5 days and drinking water for the next 2 days; BOC2 
was injected i.p. on days 7-10; animals were evaluated during 11 days for clinical signs. (A) 
Representative sections of colon mucosa obtained on day 11 from control, BOC2, DSS and 
DSS+BOC2 groups in WT and TNFR1-/- ;  (B) MPO (myeloperoxidase) activity in ng/mg tissue 
protein. Data are mean ± SEM. n = 4 animals/group. Magnification: 200x.  
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Table 1. Clinical data of UC patients and healthy volunteers 
 
  Treatment groups 
Characteristics  GC anti-TNF-α Healthy volunteers 
Age 31 ± 0 28 ± 2.7 60 ± 8 
Sex 
 
female - - 66% 
male 100% 100% 34% 
Histopathology 
moderate 50% 100% - 
severe 50% - - 
Colonoscopy 
moderate 100% 100% - 
severe - - - 
Treatment time (years) 0.4 ± 0 0.8 ± 0.4 - 
Number of clinical signs 4.5  0.5 1  1 - 
Epithelial AnxA1 expression ++ ++ +++ 
 
GC = glucocorticoids. Clinical signs include diarrhea, bloody feces, abdominal pain, fever, 
urgency and extraintestinal manifestations. Numbers are expressed as mean  SEM or 
percentages (%). 
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